Introduction
The transcriptional coactivators p300 and CBP are highly conserved paralogous proteins, first identified by their interactions with adenoviral E1A and CREB (cAMP response element binding protein) respectively (Chrivia et al., 1993; Eckner et al., 1994) . p300/CBP regulate gene expression through interactions with nuclear proteins and participate in a broad spectrum of biological activities, including cell cycle regulation, differentiation, apoptosis and the DNA damage response (Giordano and Avantaggiati, 1999; Goodman and Smolik, 2000) . Both genes are targeted in a range of cancers: truncating and point mutations in epithelial cancers, and translocations in leukemias. This has led to the suggestion that p300 and CBP may function as classical tumor suppressor genes (Gayther et al., 2000; Ozdag et al., 2002; Iyer et al., 2004b; Ward et al., 2005) . p300 and CBP function as prototype histone and factor acetyltransferases (HAT and FAT) by catalyzing the addition of an acetyl group to specific lysine residues on histones and other proteins, including p53, retinoblastoma (RB) and E2F (Gu and Roeder, 1997; Liu et al., 1999; Martinez-Balbas et al., 2000; Chan et al., 2001) . Early experiments have suggested that the two homologs play interchangeable, apparently redundant roles in cell physiology. However, it is becoming increasingly clear that p300 and CBP have distinct, nonoverlapping functions in several pathways, such as the p53 response (Grossman, 2001; Iyer et al., 2004a) .
The role of p300 and CBP in cell cycle control remains controversial, partly due to the lack of a robust experimental system where cell cycle progression can be analysed in detail. Several experiments have implicated p300, and to a lesser extent CBP, in G1/S transition, but with apparently contradictory results. The inability to culture p300 À/À MEFs has precluded its use in cell cycle experiments (Yao et al., 1998) , and studies have been limited to experimental systems where p300 has either been overexpressed or partially depleted. Overexpression of adenoviral E1A, which sequesters p300, drives fibroblasts prematurely into S phase (Yang et al., 1996) . However, the effect of E1A is nonspecific as it also interacts with RB and p21, two proteins that modulate G1/S transition (Sherr and McCormick, 2002) . Depleting both p300 and CBP in NIH3T3 cells using antibody microinjection, inhibits S-phase entry and results in G1/S arrest (Ait-Si- Ali et al., 2000) . In separate experiments, transient knockdown of p300 and CBP (individually or together) using specific antisense oligonucleotides, resulted in inappropriate DNA synthesis and S-phase progression (Kolli et al., 2001; Rajabi et al., 2005) . However, due to the transient nature of p300/ CBP depletion, these results were based on observations during a single cell cycle, and not on normally cycling cells. Conversely, stable overexpression of p300 in fibroblasts delays S-phase entry (Baluchamy et al., 2003) . In interpreting these experiments, it has been suggested that the G1/S transition is regulated through variable activation of c-myc and c-myc-dependent targets (Kolli et al., 2001; Baluchamy et al., 2003; Rajabi et al., 2005) .
In cycling epithelial cells, the RB-E2F pathway serves as a focal point controlling G1-to S-phase transition. Upstream modulation of RB activity depends on the coordinate activity of several cyclin-dependent kinases (cdks) that hyperphosphorylate RB during G1 (Sherr and McCormick, 2002) . In the currently accepted model, RB is hypophosphorylated during early G1, and binds strongly to E2F, thus preventing transcription of E2F target genes. As G1 progresses, RB is sequentially hyperphosphorylated and inactivated: initially by early/mid-G1 cdks (cdk6 and cdk4), and subsequently by late G1 cdks (cdk2). RB hyperphosphorylation releases E2F, which transactivates target genes that promote S-phase entry. There is mounting evidence that both p300 and CBP play key roles in regulating this pathway. Several groups have shown that p300/ CBP and another HAT, p/CAF (p300/CBP associated protein), function as coactivators of E2F-mediated transactivation (Martinez-Balbas et al., 2000) . Furthermore, direct modulation of RB function through p300/ CBP-mediated acetylation has been reported, leading to the suggestion that RB acetylation regulates G1/S transition (Chan et al., 2001) . Others have shown that acetylation of RB by p300 and p/CAF activates differentiation-specific pathways and cell cycle exit but plays no apparent role in G1/S transition (Nguyen et al., 2004) .
In this report, we examine the role of p300 in cell cycle progression using the somatic cell line knockout model we had previously generated (Iyer et al., 2004a) . Unlike p300 À/À MEFs, p300-deficient (p300 À ) cells (derived from the colorectal carcinoma cell line HCT116) could be propagated in culture, hence providing an ideal system to perform these cell cycle experiments.
Results

Cell cycle profile of p300
À cells p300-deficient (p300 À ) cells were generated by gene targeting the well-characterized HCT116 colorectal cancer cell line (Iyer et al., 2004a) . The parental HCT116 cells express a protein truncated downstream of the HAT domain (hence only detectable with the N-terminal antibody), which has been shown to be functionally normal (Sakaguchi et al., 1998; Sun et al., 2000; Iyer et al., 2004a) . We have previously shown that the single HCT116 allele that is expressed was disrupted by homologous recombination, generating a p300 null cell line (p300 À ). p300
À cells had significant proliferation defects when grown under optimal cell culture conditions, compared to parental HCT116 cells (Iyer et al., 2004a) . The prolongation of doubling times seen in p300
À cells was unsurprising, as similar growth defects had been reported in fibroblasts from p300 knockout mice (p300 À/À MEFs) and cell lines with ribozyme-mediated p300 knockdown (Yao et al., 1998; Yuan et al., 1999) . However, cell cycle profiling of asynchronous cultures (using BrdU incorporation assays) revealed that the distribution of cells in G1 and S phases differ significantly depending on p300 status (Iyer et al., 2004a) . In HCT116 cultures, 44% of cells were in G1, compared with 33% of p300 À cells (Po0.05). In contrast, 45% of p300 À cells were in S phase, compared with 36% of HCT116 (Po0.05). These results suggest that resident time in G1 phase is disproportionately shorter in p300 À compared to parental HCT116 cells.
Loss of p300 results in a G1/S transition defect One possible explanation for the abnormal cell cycle distribution in p300 À cells is that G1 to S phase transition may have been deregulated. To determine whether p300 loss could affect this transition, we performed synchronization-release experiments to characterize progression through G1-and S-phase entry in HCT116 and its p300 knockout derivative (p300 À ) (Figure 1) . Parallel experiments were also conducted on p300
À cells transfected with either wild-type (wt) p300 (cytomegalovirus (CMV)wt rescue) or p300 with a point mutation in the HAT domain, which inactivates its enzymatic activity (CMVdy rescue). All experiments were performed in at least two independently targeted p300 À clones. Serum depletion for 24 h resulted in G1/G0 arrest in an identical fraction (between 75 and 80%) of HCT116, p300 À , CMVwt-rescue and CMVdy-rescue cells (data not shown). S phase fractions were determined by quantifying BrdU incorporation (by microscopy) after release into fresh media. At 8-10 h after release, approximately 70% of p300 À cells were in S phase, while HCT116 cells required more that 15 h to reach this stage À and rescue cells. Western blots showing p300 levels in HeLa, MT3, HCT116, three independently targeted p300
À clones (p300 À 1, p300 À 2, p300 À 3), EFwt rescue (p300 expression driven by the elongation factor-1a promoter), CMVwt rescue and CMVDY rescue (p300 expression driven by the CMV promoter) (with b-actin loading control). p300 controls G1/S transition in cancer cells NG Iyer et al ( Figure 2A ). Rescue cells, whether transfected with the wt or HAT-deficient constructs, had S-phase fractions identical to HCT116 cells. This shows that p300 HAT activity is dispensable in the control of G1/S transition. These findings were confirmed by flow cytometry: p300 À cells traversed G1 rapidly and entered S phase earlier than HCT116 or rescue cells (Supplementary Figure  1A) . To verify that these findings were a consequence of abnormal G1/S transition and not due to differences in G0/G1 cell cycle re-entry, cells were synchronized by mitotic arrest and released into G1. This was performed by prolonged nocodazole treatment, harvesting mitotic cells by vigorous shaking and plating them into fresh media. S-phase fractions were determined by BrdU incorporation. These experiments again showed that p300 À cells entered S phase much earlier than HCT116 and rescue cells ( Figure 2B ). Cell cycle profiling by flow cytometry confirmed these observations (Supplementary Figure 1B) .
To ensure that premature G1/S transition secondary to p300 loss was not a phenomenon unique to HCT116, we repeated these experiments on a different cell line. We generated p300 knockdowns in the MT3 cell line using RNAi (p300KD-MT3). The MT3 cell line is a colorectal carcinoma cell line, which is wt for p300, p53 and RB. RNAi-mediated depletion resulted in p300 expression levels that were significantly (but not completely) reduced compared to wt MT3 or MT3 cells transfected with an empty vector (MT3 m) ( Figure 2C ). CBP expression was unaffected by the RNAi construct used (data not shown). Serum-depletion and release experiments performed on these cells showed rapid S-phase entry, comparable to what was observed in p300 À cells ( Figure 2D ). These results demonstrate that p300 loss leads to rapid G1/S transition under two different conditions: release from serum-depletion induced G1/G0 arrest and from nocodazole-mediated mitotic arrest. The results also show that p300 HAT activity is dispensable for this function. Therefore, p300 appears to be essential for orderly G1/S transition.
Early S-phase entry in p300-deficient cells is associated with premature RB phosphorylation To identify mechanisms responsible for the defect in p300-deficient cells, expression levels of proteins known to regulate G1/S transition (total RB, phosphorylated-RB, acetylated-RB, cyclin A, cyclin D, cyclin E, mcm2, p21 and c-myc) were analysed in HCT116 and p300 À cells, after serum-depletion and release. In both HCT116 and p300
À cells, total RB levels remained constant throughout this time course. In p300 À cells, however, RB was found to be phosphorylated earlier than parental HCT116 cells ( Figure 3a ). To determine levels of RB acetylation across these time course experiments, we performed IP Westerns. Results were similar whether immunoprecipitating RB and blotting with acetyl-lysine antibodies (Figure 3b ), or using the reciprocal approach (data not shown): acetylation of RB was unaffected by p300 disruption. These results support the contention that p300 is not the principal RB acetylase (Nguyen et al., 2004) . While RB acetylation appeared to peak at 15 hours in p300 À cells, it continued to increase for up to 24 h in parental HCT116.
To determine if early RB phosphorylation resulted in activation of E2F downstream targets, levels of cyclin E, cyclin A and mcm2 were determined by Western blot. In p300 À cells, both cyclin E and mcm2 levels increased early in G1 in parallel with premature RB phosphorylation (Figure 3c) . Cyclin E levels, which are highly specific for the G1/S boundary, decreased rapidly. In contrast, levels of cyclins D and A were identical in p300
À and parental HCT116 cells (Figure 3c ). There were no differences seen in levels of p53, c-myc and p21 (data not shown). To confirm that these results were not specific to HCT116, synchronization-release experiments were performed in MT3m and p300KD-MT3cells. Early RB phosphorylation and cyclin E activation were seen in p300KD-MT3 cells, although to a lesser degree than in p300 À cells, which is consistent with partial knockdown and residual p300 protein activity (Figure 3d) .
Analysis of cells subject to nocodazole-arrest and release showed similar results (Figure 3e ). Initial levels of RB phosphorylation were high after nocodazole arrest and decreased as both HCT116 and p300
À cells re-entered G1. In p300 À cells, however, progress through G1 was associated with premature RB phosphorylation, and activation of E2F targets cyclin E and mcm2. These changes were coincident with rapid progression through G1 and early S-phase entry.
These results show that premature S-phase entry secondary to p300 loss is associated with early RB phosphorylation and activation of E2F targets such as cyclin E.
Association between p300 and RB varies during G1 p300 and RB are believed to associate in vivo, although it is not clear if this interaction is direct or indirectly mediated through factors such as E1A (Chan et al., 2001; Nguyen et al., 2004) . To demonstrate p300/RB association in the absence of E1A, we performed coimmunoprecipitation (Co-IP) experiments in two cell lines, HCT116 and HeLa, which express both proteins, with p300
À cells used as negative controls. Co-IPs were performed in both orientations: immunoprecipitating RB and blotting with p300 antibody and vice versa. In asynchronous cultures, co-IP experiments showed that p300 and RB associate in both HCT116 and HeLa cells. In contrast, no p300 band was seen in RB immunoprecipitates of control p300 À cells (data not shown). To determine whether the p300-RB association changes during the cell cycle, co-IPs were performed on cells synchronized by serum starvation. During time-course experiments of cells released into serum-containing media, cell cycle progression was monitored using flow cytometry (see above), and total RB and p300 levels remained constant (Figure 4a ). Co-immunoprecipitation, using RB antibodies to IP and p300 antibodies to blot, showed a marked variation in p300-RB association, as cells progressed through G1. In HCT116 cells, binding between p300 and RB was maximal 1 h after release into cycle (Figure 4b ). This interaction decreased rapidly as cells progressed through G1, and peaked again in late G1 (although to a lesser degree). A similar pattern was observed in HeLa cells (Figure 4c ). In contrast, this bimodal p300-RB association was not seen when phospho-RB antibodies were used to IP RB: no association in early G1, with a faint band seen in late G1 (Figure 4d ). Reciprocal co-immunoprecipitation experiments in HCT116 cells (which take advantage of the difference in migration patterns of hyper-and hypophosphorylated RB in sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE)) show that in early G1, p300 associates predominantly with hypophosphorylated RB (Figure 4e ). This interaction peaked 1 h after release, then decreased as cells progressed through G1. In late G1, there was a second peak in p300-RB binding, mostly involving hyperphosphorylated RB. Co-IP of CBP and RB did not show the early G1 peak under identical conditions (Figure 4f ). These results suggest that there is an increased association between RB and p300 (but not CBP) in early G1, and that this interaction is mostly with the hypophosphorylated form of RB. p300 directly inhibits cdk6, and promotes cdk2-dependent RB kinase activities To determine if the p300-RB association during G1 interferes with cdk-mediated RB phosphorylation, we performed in vitro kinase assays with cdks that phosphorylate RB: cyclinD/cdk4 and KSVcyclin/cdk6 in early/mid-G1, and cyclinE/cdk2 in late G1. KSVcyclin/ cdk6 was used as an alternative to cyclinD/cdk6 since it has a more consistent in vitro activity, particularly in phosphorylating histone H1. Recombinant RB and histone H1 were used as substrates for these reactions. Results were identical whether substrates were added individually ( Figure 5 ) or mixed together in the same (e) p300 IP on HCT116 cells, blotted with RB and p300 antibodies, showing hyper-and hypophosphorylated forms of RB (hyper-P and hypo-P, respectively)(f) RB-IP on HCT116 cells, blotted with CBP and RB antibodies. In these experiments cells were serum starved, and harvested after release into fresh media for the indicated time periods. In all IPs, input refers to whole cell lysates of asynchronous cultures. p300 controls G1/S transition in cancer cells NG Iyer et al reaction (data not shown). Histone H1 phosphorylation was unaffected by recombinant p300 protein. In contrast, addition of recombinant p300 decreased KSVcyclin/cdk6-dependent RB phosphorylation, and augmented the RB-kinase activity of cyclinE/cdk2 ( Figure 5 ). There was no significant phosphorylation of p300 seen under these circumstances (data not shown). Kinase activity of cyclinD/cdk4 was not affected. These results show that p300 directly inhibits RB phosphorylation by the early G1 kinase cdk6, and increases the activity of the late G1 kinase, cdk2. Importantly, p300 itself was unaltered and hence it does not function as a competitive inhibitor.
RB abnormalities in p300-deficient cells results in serum-independent growth
The RB pathway controls cell cycle progression in response to mitogenic stimuli (Sage et al., 2003) . HCT116 and MT3 undergo G1/G0 arrest when cultured for prolonged periods without serum, as a result of RB hypophosphorylation. To examine the effect of p300 loss on RB-mediated cell cycle arrest, cells were cultured in serum-depleted media. In HCT116 RB phosphorylation was reduced after 96 h of serum depletion (Figure 6a ). In contrast, phospho-RB levels remained high in p300 À cells even after prolonged serum starvation, and this was reversed when p300 was restored (EFwt rescue). For these experiments, rescue cells were generated by transfecting a p300 expression construct under the control of the EF promoter (human elongation factor 1a promoter), since this results in more sustained expression compared with CMV-promoterdriven p300 expression (Suganuma et al., 2002) . To analyse the fraction of cycling cells BrdU incorporation assays were used (Figure 6b ). In HCT116 and p300 À cells, there was a dramatic drop in BrdU incorporation after 24 h of serum depletion. This result was consistent with the observed identical fractions of cells in G1/G0 (see above: Figure 2a) . After 72-96 h of serum depletion, the fraction of HCT116 cells incorporating BrdU continued to decline and reached negligible levels ( Figure 6b ). This was associated with reduced levels of RB phosphorylation (Figure 6a ). In contrast, p300 À cells continued to incorporate BrdU in association with high levels of phosphorylated RB. During this period, there was no discernible difference in apoptosis between p300 À and parental cells (data not shown). Surprisingly, p300
À cells which are growth impaired in regular serumcontaining media, showed faster growth rates in serumdepleted media, than parental HCT116 and rescue cells (Figure 6c) .
The growth pattern of MT3 m and p300KD-MT3 cells grown in serum-depleted media was also analysed using MTT assays. These experiments revealed that p300KD-MT3 cells continued to proliferate after 72 h of serum-depletion, in contrast to MT3m cells (Figure 6d) .
These results suggest that cells deficient in p300 have lost their dependence on serum-derived factors normally required for cell cycle progression, and this was associated with (and might be mediated by) defects in RB phosphorylation.
Discussion
The role of p300 in epithelial cell cycle regulation has remained difficult to assess due to the lack of an appropriate experimental system. Gene targeting in HCT116 has been used successfully to characterize the role of several proteins involved in cell cycle regulation (Waldman et al., 1995; Chan et al., 1999) . The ability to propagate p300 À cells and generate rescue clones provided us with an experimental system to test p300 function in cycling epithelial cells.
We had previously reported significant proliferation defects in p300 À cells (Iyer et al., 2004a) . Here, we made a similar observation using p300-deficient MT3 knockdowns (Supplementary Figure 2) . These findings are consistent with other experimental systems where p300 levels are artificially reduced (Yao et al., 1998; Yuan et al., 1999) . Surprisingly, despite slower doubling rates compared to HCT116, fewer p300 À cells were in G1 at any given time. Previously, it had been noted that lowering p300 levels in human mammary epithelial and fibroblast cell lines accelerated S-phase entry and early DNA replication (Kolli et al., 2001) . Hence, we asked whether a shortened G1 phase secondary to p300 loss, could explain the observed cell cycle distribution. Synchronization and release experiments using two different methods showed that p300 À cells have shortened G1 and premature S-phase entry. By using two different synchronization methods, we could conclude the observed phenotype was secondary to true deregulation of G1/S transition, and not simply a consequence of abnormal cell cycle re-entry. Similar results were obtained using MT3 cells. Remarkably, reversal of the phenotype by transfecting a HAT-dead p300 point mutant showed that the acetyl-transferase activity was dispensable. Based on these results, we conclude that p300 is required for orderly G1/S transition and for preventing premature S-phase entry independently of its HAT activity.
Previous data ascribing a role for p300 and CBP in G1/S control have been inconsistent, probably due to the lack of appropriate experimental models, or differences in interpreting results obtained. Our results are in agreement with data from one group, where antisense oligonucleotides were used to demonstrate that specific depletion of p300 and/or CBP promotes premature DNA synthesis and S-phase entry in immortalized human mammary epithelium (MCF10A) and fibroblast cell lines (Kolli et al., 2001; Rajabi et al., 2005) . In these experiments, the resultant phenotype was attributed to differences in c-myc expression, and the authors concluded that p300 and CBP played important roles in G1/S transition. However, this hypothesis was based on observations limited to the serum-depleted condition required for transfection, in noncycling cells. Under these circumstances, the aberrant DNA synthesis seen could alternatively reflect abnormalities in G0 exit or in the cellular response to growth factor depletion, rather than defects in G1/S transition. Of note, further addition of serum resulted in uniform apoptosis of transfected cells, preventing further analysis. In contrast, our experimental model utilized cells in which p300 levels were stably reduced, and could be propagated in culture with no increase in apoptosis. To specifically address G1/S transition, two distinct synchronization-release strategies were utilized, to assess the progress of cycling cells through G1/S from G0 or M phases. No measurable differences were observed in c-myc levels between parental and p300-depleted cells (data not shown), excluding c-myc as the culprit of our observations. Instead, accelerated G1/S progression was associated with premature RB hyperphosphorylation, and activation of E2F targets, cyclin E and mcm2. p300/CBP-mediated RB acetylation had previously been shown to inhibit RB phosphorylation (Chan et al., 2001 ). However, as there was no difference in RB acetylation between HCT116 and p300 À cells, this could not account for the results seen. In fact RB acetylation was not measurably different in p300 À cells, suggesting that p300 is not the principal RB acetylase in vivo. Recently is has been reported that RB acetylation in vivo is mainly carried out by p/CAF, and that its main function is the control of differentiation and cell cycle exit, not G1/S transition (Nguyen et al., 2004) .
Co-IP experiments suggest that in early G1, p300 binds to hypophosphorylated RB and inhibits cdk6-dependent phosphorylation, possibly by direct steric hindrance. This role is p300-specific, as CBP does not appear to associate with RB in early G1, and the presence of intact CBP is unable to compensate for the defect. A second peak in the interaction between p300 and RB was seen at the G1/S boundary when cdk2 activity is maximal. p300-augmented cdk2 kinase activity, suggesting that the late G1 p300-RB interaction facilitates cell cycle progression. This role in late G1 probably overlaps with CBP, as CBP also associated with RB in late G1, and S-phase entry was not compromised in p300 À cells. We propose a model where p300 has a dual role in regulating G1/S transition. In early G1, p300 binding inhibits cdk6-mediated RB hyperphosphorylation, whereas in late G1, p300 facilitates RB phosphorylation, possibly in conjunction with CBP. Our experiments do not answer whether the association between p300 and RB is a direct interaction or mediated by an intermediate factor. Possible intermediaries of the interaction include E1A and p/CAF (Chan et al., 2001; Nguyen et al., 2004) . E1A is an unlikely candidate as the cell lines used here did not express it. In vitro kinase experiments showed that p300 was able to directly alter RB phosphorylation, providing circumstantial evidence that this modulation is not necessarily dependent on cointeracting factors. Future experiments will help clarify this important issue: in vitro binding assays could be used to map domains involved in p300/RB protein-protein interaction and multiprotein p300-containing nuclear complexes could be isolated through the cell cycle, to identify binding partners using mass spectrometry.
Acute disruption of the RB pathway is sufficient to induce re-entry into cycle of MEFs made quiescent by serum depletion (Sage et al., 2003) . The regulation of RB phosphorylation is an important mechanism of cell cycle control under serum starvation. Here, p300 absence was associated with continued hyperphosphorylation of RB under serum starvation and failure of p300 À cells to arrest. Remarkably, under these conditions p300-deficient cells proliferated more efficiently than their parental lines. These results suggest that the absence of p300 deregulates the RB pathway, with failure to enforce the G1/S transition checkpoint resulting in acquired serum/growth factor independence. Mutational analyses have shown that truncating (loss of function) p300 mutations occur in a number of epithelial cancers. Deregulation of RB function and the consequent serum independence could be the mechanism through which p300 mutations induce cellular transformation.
In conclusion, these experiments show that p300, besides regulating proliferation, controls G1/S transition through modulation of RB phosphorylation during G1. The presence of intact CBP is unable to compensate for these abnormalities, supporting the nonoverlapping functions of p300 and CBP in epithelial biology. These experiments also suggest a novel mechanism through which p300 may function as a classical tumor suppressor.
Materials and methods
Cell culture, generation of KD cells and synchronization-release experiments HCT116 (ATCC, Manassas, VA, USA) and its derivatives were cultured in McCoy's 5A medium with 10% fetal calf serum (FCS) and penicillin/streptomycin (Invitrogen, Paisley, UK). HeLa, MT3 (ATCC) and its derivatives were cultured in Dulbecco's Modified Eagle's medium (DMEM) (Invitrogen) with 10% FCS and penicillin/streptomycin. p300 gene targeting was performed as previously described (Iyer et al., 2004a) . Rescue clones were made by co-transfecting pcDEF-Flag-p300 (p300 expression vector driven by the elongation factor-1a promoter) (kind gift from MA Ikeda), CMVb-p300 or CMVbp300DY (p300 expression vectors driven by the CMV promoter) (kind gifts from TP Yao), with pPGK-Puro at a 10:1 ratio, and selecting with 1 mg/ml Puromycin (Sigma, Cambridge, UK) for 24 h. In each case, p300 expression levels were determined at the start of every experiment. The mammalian expression vector, pSUPER.retro (OligoEngine) was used to generate p300 knockdowns by RNA interference in MT-3 cells. The sequence used to knockdown p300 was 5 0 -gcagtcctggattaggttt-3 0 . MT3 cells were transfected with the resultant construct, using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Stable transfectants were selected with 0.5 mg/ml puromycin for 7 days. All experiments were performed on two independently generated MT3 knockdown clones (p300KD-MT3), parental MT3 cells and MT3 clones transfected with empty pSUPER. retro vector (MT3m). p300 À and p300KD-MT3 stock cultures were propagated in the presence of 500 mg/ml G418 (Sigma) and 0.5 mg/ml puromycin, respectively. All experiments were performed in the absence of antibiotic selection. Serum depletion was carried out by replacing media with serum-free DMEM for the indicated periods of time, and released into fresh, serumenriched media. Mitotic arrest was carried out by incubating cells in media containing 0.2 mg/ml nocodazole (Sigma) for 15 h. Mitotic cells were obtained by vigorous shaking of the flasks, and reculturing of supernatant cells in fresh media. Pulsing with 5-bromo-2-deoxy-uridine (BrdU) (Sigma) was performed by incubating cells in 50 mM BrdU for 15 min before harvesting.
Immunoblotting, immunoprecipitation and immunofluorescence
Western blots and immunoprcipitations were performed as previously described (Iyer et al., 2004a) . All experiments were performed in triplicate and images shown are representative examples. Immunofluoresence, to detect BrdU incorporation, was performed as described (Dimitrova et al., 1999) . Antibodies used were p300 N-terminal (N-15) p300 C-terminal (C-20), CBP (A-22), p53 (DO-1), RB, (C-15), RB (IF8), c-myc (9E10) (Santa Cruz Biotechnologies, Santa Cruz, USA); p21 WAF1 (Ab-1) (Oncogene Research Products, San Diego, USA); phospho-RB (Ser807/ 811), pan-acetyl-lysine (monoclonal) (Cell Signalling Technologies, Hitchin, UK); cyclin A (6E6), cyclin D1 (P2D11F11), cyclin E (G2a), mcm2 (G1) (Novocastra, Newcastle-upon-Tyne, UK); b-actin (AC-15) (Abcam, Cambridge, UK); fluorescein isothiocyanate (FITC)-BrdU (N1031) (BD Biosciences, Oxford, UK); and BrdU (Cell Proliferation Kit) (Amersham, Pollards Wood, UK). RB and p300 co-IPs were performed using RB (IF8 or C-15) and p300 (N-15) antibodies to IP, and p300 (N-15 for HCT116 or C-20 for HeLa), CBP (A-22) and RB antibodies to blot. RB acetylation was determined both by using RB (C-15) antibody to IP and pan-acetyl-lysine antibody to blot, and vice versa.
Analysis of cell cycle profile and apoptosis
For cell cycle analysis, cells were fixed in 70% ethanol and stained with 0.02 mg/ml propidium iodide (PI). Profiles were obtained by flow cytometry using the BD FACScalibur flow cytometer. BrdU incorporation assays by flow cytometry was performed using FITC-conjugated anti-BrdU monoclonal antibody (BD Biosciences, Oxford, UK) and PI, as described (Dolbeare et al., 1990) . In each experiment, data were obtained from 10 3 cells, and each experiment was performed in triplicate.
In vitro kinase assays Recombinant p300 and RB proteins were synthesized as described using baculoviral p300 constructs (kind gift from p300 controls G1/S transition in cancer cells NG Iyer et al Dr WL Kraus and Dr J Kadonaga) and pGEX-RB (Hagemeier et al., 1993; Kraus and Kadonaga, 1998) . Recombinant RB (0.1-2 mg) was preincubated either with recombinant p300 (1-10 mg) (eluted in 10 mM TRIS pH 7.5, 0.1 % NP-40, 0.2 M NaCl, 10% glycerol, 250 mM imidazole) or equal volume carrier buffer, for 10 min at room temperature in kinase buffer (final concentration 50 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid pH 7.5, MgCl 2 , 1 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride, 10 mM b-glycerophosphosphate, 10 mM adenosine 5 0 triphosphate (ATP) and 5 mM MnCl 2 ). Subsequently, one microlitre of cyclinD1/cdk4, cyclinE/cdk2 or KSVcyclin/cdk6 (obtained as generous gifts from Dr Sybille Mittnacht) was added to the reaction mix, and incubated for a further 10 min at 301C. Reactions were stopped by adding 3 Â Laemmli buffer, and samples were subjected to SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. Immunoblotting was performed using phospho-RB (ser807/811) and RB (C15) antibodies. The ratios of RB to p300 used in these assays had to be optimized, and maximal effects were seen with 0.5 mg RB and 5 mg p300. Recombinant histone H1 was used as negative controls. This was incubated with p300 and respective kinases as described before, however with the additional presence of 0.2 mCi g-32 P ATP. Samples were subjected to SDS-PAGE and transferred to PVDF membranes. Incorporation of the radioactive phosphate group was directly visualized by exposing membranes to X-ray films.
